Richard Chazal

We're extraordinarily fortunate to have these wonderful new tools that science shows us can potentially improve outcomes, how to use them is something we are still working through but I think we will see increased uptake in the next 12 months.

Cost is a problem, there is concern on the part of many clinicians that if patients are reasonably stable and one starts a new medicine then they may become discouraged by the cost and actually stop taking medication.